Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer

BACKGROUND: Pembrolizumab is approved for patients with metastatic, microsatellite instability (MSI)‐high or mismatch repair‐deficient (dMMR) solid tumors. However, very few men with prostate cancer were included in these initial studies. METHODS: We performed a single institution retrospective revi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Med
Hauptverfasser: Tucker, Matthew D., Zhu, Jason, Marin, Daniele, Gupta, Rajan T., Gupta, Santosh, Berry, William R., Ramalingam, Sundhar, Zhang, Tian, Harrison, Michael, Wu, Yuan, Healy, Patrick, Lisi, Stacey, George, Daniel J., Armstrong, Andrew J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2019
Schlagworte:
Clinical Cancer Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6712455/
https://ncbi.nlm.nih.gov/pubmed/31270961
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2375
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge